GlassScriptPhysician profile
Phirin Kennedy
NPI 1891093704
$693.07
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $679 · 2022: $14.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.49 | 2021 | |
| Redhill Biopharma INC. | $92.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.86 | 2021 | |
| Janssen Biotech, INC. | $33.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.14 | 2021 | |
| Qol Medical, LLC | $15.91 | 2021 | |
| Braintree Laboratories, INC. | $14.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.48 | 2022 | |
| Merck Sharp & Dohme LLC | $13.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phirin Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.